Systematic pan‐cancer analysis insights into ICAM1 as an immunological and prognostic biomarker
The FASEB Journal · 2024
DOI: 10.1096/fj.202302176r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2024. Verfasst von Chunjiao Yang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Fifth Affiliated Hospital of Guangxi Medical University & The First People's Hospital of Nanning, Nanning, China. Hauptthemen laut MEDLINE: Intercellular Adhesion Molecule-1, Biomarkers, Tumor, Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 53 Literaturangaben.
Abstract (Originalsprache)
Intercellular adhesion molecule 1 (ICAM1) is a cell surface adhesion glycoprotein in the immunoglobulin supergene family. It is associated with several epithelial tumorigenesis processes, as well as with inflammation. However, the function of ICAM1 in the prognosis of tumor immunity is still unclear. This study aimed to examine the immune function of ICAM1 in 33 tumor types and to investigate the prognostic value of tumors. Using datasets from the Cancer Genome Atlas (TCGA), Genotype Tissue Expression (GTEx), Cancer Cell Lines Encyclopedia (CCLE), Human Protein Atlas (HPA), and cBioPortal, we investigated the role of ICAM1 in tumors. We explored the potential correlation between ICAM1 expression and tumor prognosis, gene mutations, microsatellite instability, and tumor immune cell levels in various cancers. We observed that ICAM1 is highly expressed in multiple malignant tumors. Furthermore, ICAM1 is negatively or positively associated with different malignant tumor prognoses. The expression levels of ICAM1 were correlated with the tumor mutation burden (TMB) in 11 tumors and with MSI in eight tumors. ICAM1 is a gene associated with immune infiltrating cells, such as M1 macrophages and CD8+ T cells in gastric and colon cancer. Meanwhile, the expression of ICAM1 is associated with several immune‐related functions and immune‐regulation‐related signaling pathways, such as the chemokine signaling pathway. Our study shows that ICAM1 can be used as a prognostic biomarker in many cancer types because of its function in tumorigenesis and malignant tumor immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The Fifth Affiliated Hospital of Guangxi Medical University & The First People's Hospital of Nanning, Nanning, China.
- The First Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, China.
- Benxi Central Hospital, Benxi, China.
- Shenzhen Longhua Maternity and Child Healthcare Hospital, Shenzhen, China.
- Department of Respiratory Medicine, The Fifth Affiliated Hospital of Guangxi Medical University & The First People's Hospital of Nanning, Nanning, China.
ORCID-Profile: Chunjiao Yang, Bingqiang Ni, Ling Shen, Zhenlong Li, Lu Zhou, Huayun Wu, Yuzhe Zhang, Ling Liu, Liansheng Tian, Lirong Yan, Xin Jin
Zitieren
APA
Yang, C., Ni, B., Shen, L., Li, Z., Zhou, L., Wu, H., Zhang, Y., Liu, L., Liu, J., Tian, L., Yan, L., & Jin, X. (2024). Systematic pan‐cancer analysis insights into ICAM1 as an immunological and prognostic biomarker. The FASEB Journal. https://doi.org/10.1096/fj.202302176r
Vancouver
Yang C, Ni B, Shen L, Li Z, Zhou L, Wu H, et al. Systematic pan‐cancer analysis insights into ICAM1 as an immunological and prognostic biomarker. The FASEB Journal. 2024. doi:10.1096/fj.202302176r
BibTeX
@article{Yang2024,
author = {Yang, Chunjiao and Ni, Bingqiang and Shen, Ling and Li, Zhenlong and Zhou, Lu and Wu, Huayun and Zhang, Yuzhe and Liu, Ling and Liu, Jiao and Tian, Liansheng and Yan, Lirong and Jin, Xin},
title = {Systematic pan‐cancer analysis insights into ICAM1 as an immunological and prognostic biomarker},
journal = {The FASEB Journal},
year = {2024},
doi = {10.1096/fj.202302176r}
}
EUVIMED